Study of significance of p53 expression in primary ovarian tumour

Abstract

The purpose of the study was to understand the molecular changes that happen in human cancer, P53 gene mutation. Here, with respect to P53 immunohistochemical staining were taken into consideration as the surrogate for the mutational analysis. This was used for the diagnosis of ovarian cancer. The main aim of the study was to evaluate the immunohistochemical frequency of the P53 and to correlate its expression with the prognosis. In the current study 107 cases associated with ovarian cancer were studied. The samples received were hysterectomy as well as unilateral and bilateral salpingo-oophorectomy specimens, which were fixed in 10% neutral buffer formalin and processed routinely. 68.7% of the patients showed P53 malignant ovarian tumours. In the benign, it was considered as negative or in the position of borderline tumour. No statistically significant correlation was shown between the age and P53 expression. There was statistically significant difference between borderline, benign and the malignant tumors. It was also assessed that there was a statistically significant difference between P53 expression and serous carcinoma in the current study. The present study concludes that P53 tumor gene was found to be mutated in more than the 50% of the human cancer and was expressed as the aberrant form of protein. The study also concludes that in borderline tumor, P53 rarely mutates and is results in poor prognosis.